NVOS Stock Overview
Provides multidisciplinary primary care and related wellness products and services in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Novo Integrated Sciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.037 |
| 52 Week High | US$1.41 |
| 52 Week Low | US$0.027 |
| Beta | -0.90 |
| 1 Month Change | -32.75% |
| 3 Month Change | -87.47% |
| 1 Year Change | -96.54% |
| 3 Year Change | -99.74% |
| 5 Year Change | -99.92% |
| Change since IPO | -99.96% |
Recent News & Updates
Recent updates
Slammed 49% Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Screens Well Here But There Might Be A Catch
Jul 11
Novo Integrated Sciences, Inc. (NASDAQ:NVOS) Looks Just Right With A 26% Price Jump
Apr 18Novo Integrated Sciences prices 4M unit public offering at $.50/unit
Oct 14Novo Integrated Sciences expects to report over fivefold increase in Q3 revenue
Jul 11Health Check: How Prudently Does Novo Integrated Sciences (NASDAQ:NVOS) Use Debt?
Nov 23Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Aug 07Does Novo Integrated Sciences (NASDAQ:NVOS) Have A Healthy Balance Sheet?
Mar 02Shareholder Returns
| NVOS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 15.6% | -0.2% | -2.2% |
| 1Y | -96.5% | -9.4% | 23.9% |
Return vs Industry: NVOS underperformed the US Healthcare industry which returned -9.4% over the past year.
Return vs Market: NVOS underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| NVOS volatility | |
|---|---|
| NVOS Average Weekly Movement | 40.8% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NVOS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NVOS's weekly volatility has increased from 32% to 41% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 190 | Rob Mattacchione | www.novointegrated.com |
Novo Integrated Sciences, Inc., together with its subsidiaries, provides multidisciplinary primary care and related wellness products and services in Canada. It operates through two segments, Healthcare Services and Product Sales. The company offers physiotherapy, chiropractic care, manual/manipulative therapy, occupational therapy, eldercare, massage therapy, acupuncture and functional dry needling, chiropody, stroke and traumatic brain injury/neurological rehabilitation, kinesiology, vestibular therapy, concussion management and baseline testing, trauma sensitive yoga and meditation for concussion-acquired brain injury and occupational stress-PTSD, women’s pelvic health program, sports medicine therapy, assistive devices, dietitian, holistic nutrition, fall prevention education, sports team conditioning program, and private personal training services.
Novo Integrated Sciences, Inc. Fundamentals Summary
| NVOS fundamental statistics | |
|---|---|
| Market cap | US$680.69k |
| Earnings (TTM) | -US$16.17m |
| Revenue (TTM) | US$13.29m |
0.1x
P/S Ratio0.0x
P/E RatioIs NVOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NVOS income statement (TTM) | |
|---|---|
| Revenue | US$13.29m |
| Cost of Revenue | US$7.55m |
| Gross Profit | US$5.74m |
| Other Expenses | US$21.91m |
| Earnings | -US$16.17m |
Last Reported Earnings
Aug 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.82 |
| Gross Margin | 43.20% |
| Net Profit Margin | -121.61% |
| Debt/Equity Ratio | 28.3% |
How did NVOS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/24 01:19 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/08/31 |
| Annual Earnings | 2024/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Novo Integrated Sciences, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|